Biopharmaceutical News and Research

RSS

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.

25 Jul 2014

Malvern acquires MicroCal business and Affinity Biosensors' Archimedes product

Malvern Instruments Ltd (Malvern, UK) has today announced that it has completed the acquisition of MicroCal from GE Healthcare Life Sciences and has also purchased the Archimedes particle characterization system from Affinity Biosensors LLC (Santa Barbara, CA).

25 Jul 2014

New version of drug successfully treats lupus in mice

Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases.

25 Jul 2014

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire plc, the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).

23 Jul 2014

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014.

23 Jul 2014

Scientist uses samples of beating heart tissue to test effect of drugs

A Coventry University scientist has developed a pioneering new way - using samples of beating heart tissue - to test the effect of drugs on the heart without using human or animal trials.

21 Jul 2014

DARPins could revolutionize protein therapeutics

Integrating an INTEGRA VIAFLO 96 multichannel pipette into their high throughput expression facility has enabled Molecular Partners (Zurich, Switzerland) to streamline the discovery and development of a novel class of targeted protein therapeutics termed DARPins.

From INTEGRA Biosciences 15 Jul 2014

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.

11 Jul 2014

Dyadic International announces details regarding new Bakenzyme project

Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding its new Bakenzyme project.

10 Jul 2014

genOway to provide EUCOMM conditional knockout mouse models to study human diseases

genOway, the biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum München (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) announce today the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM.

3 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.

30 Jun 2014

China Biologic prices follow-on offering of common stock at $38.00 per share

China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, today announced the pricing of a follow-on offering of 1,550,000 shares of common stock at a public offering price of $38.00 per share.

27 Jun 2014

Auxilium Pharmaceuticals plans to merge with QLT

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and QLT Inc., a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT.

26 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Like all drugs, antibiotics can have side-effects when administered to people. The most common (and often benign) side effect people experience when taking antibiotics is “associated diarrhea”. This illustrates the fact that antibiotics have an impact on the intestine!

25 Jun 2014

Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain.

24 Jun 2014

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana Therapeutics, Inc., and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs).

24 Jun 2014

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain.

23 Jun 2014

Cincinnati Children’s, Alexion Pharmaceuticals establish ‘Rare Disease Innovation Fund’

Alexion Pharmaceuticals, Inc. and Cincinnati Children's Hospital Medical Center today announced the establishment of a collaboration and fund for the advancement of research in rare disease.

23 Jun 2014

Biopharmaceutical News and Research

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Malvern acquires MicroCal business and Affinity Biosensors' Archimedes product

New version of drug successfully treats lupus in mice

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Scientist uses samples of beating heart tissue to test effect of drugs

DARPins could revolutionize protein therapeutics

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

Dyadic International announces details regarding new Bakenzyme project

genOway to provide EUCOMM conditional knockout mouse models to study human diseases

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

China Biologic prices follow-on offering of common stock at $38.00 per share

Auxilium Pharmaceuticals plans to merge with QLT

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Trevena's Phase 1b data for TRV130 published in the journal Pain

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

Cincinnati Children’s, Alexion Pharmaceuticals establish ‘Rare Disease Innovation Fund’

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News